NCT04861987View on ClinicalTrials.gov

A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 18, 2021

Primary Completion Date

June 12, 2024

Study Completion Date

September 9, 2024

Conditions
Advanced CancerRefractory CancerTumor Gastric
Interventions
DRUG

PCS6422 and capecitabine

PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer. Capecitabine is a commonly used oral fluoropyrimidine.

Trial Locations (6)

10467

Processa Clinical Site, New York

22031

Processa Clinical Site, Fairfax

44106

Processa Clinical Site, Cleveland

68198

Processa Clinical Site, Omaha

87505

Processa Clinical Site, Santa Fe

08903

Processa Clinical Site, New Brunswick

Sponsors
All Listed Sponsors
lead

Processa Pharmaceuticals

INDUSTRY

NCT04861987 - A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors | Biotech Hunter | Biotech Hunter